Pediatric Hematology/Oncology
Clinical discussions on pediatric blood disorders, childhood cancers, and specialized treatment protocols.
Recent Discussions
Should targeted therapies such as Brentuximab or Crizotinib be used in the upfront management of anaplastic large cell lymphoma in a pediatric or AYA patient?
Good question. Importantly, I am assuming that the question is for ALK+ patients who have systemic disease because ALK inhibitors have no role in ALK- disease and cutaneous only ALCL is really an entirely different entity.In fact, the question is the primary aim of COG trial ANHL12P1 which uses eith...
What surveillance imaging do you obtain for stage III melanoma patients after completing systemic adjuvant therapy?
I agree with Dr. @Dr. First Last. The guidelines for surveillance allow some personalization based on patient specific characteristics. For stage III melanoma patients on adjuvant therapy (or not), we scan with CT scans every 3 months for 2 years, every 6 months up to 5 years. If there is something ...
Do you routinely check platelet counts after COVID-19 vaccines in patients with chronic ITP?
Yes. the side effects of COVID vaccines are still evolving. Mild to moderate thrombocytopenia was noted and severe thrombocytopenia is extremely rare. I would follow an abundance of caution and do weekly complete blood counts, especially in the ITP patient.
What are your indications for starting emicizumab in pediatric patients with Hemophilia A?
Emicizumab can be used for prophylaxis in the following situations: Motivated patient Patient that isn't very active Patient with Hemophilia A with inhibitors Emicizumab seems to be equivalent to regular factor. It is not a substitution for factor during bleeding episodes or for surgery.
How do you approach fertility preservation in a young child with cancer?
After the diagnosis is known, we meet with the families to discuss the known risks for infertility based on what we know about the treatment regimen they are to receive. For example, a patient with Ewing's sarcoma will receive high dose alkylators and therefore, is at significant risk for future inf...
When should upfront molecular sequencing be performed in a pediatric or AYA patient with sarcoma?
There is no standard to be able to provide a clear answer and I believe that the decision to perform sequencing would need to be determined on an individualized basis. I would consider doing so in cases of advanced disease when standard therapies are less likely to provide benefit and there is a ho...
Do you think there is any compelling data to support giving brentuximab as frontline therapy for pediatric patients with Hodgkin lymphoma?
Yes and no. It is clear that you can cure patients with pediatric HL without the use of brentuximab vedotin. While I believe it is safe and effective, if it is not covered by insurance, I would not advocate for its use in low and intermediate risk pediatric patients.However, for HR pediatric patient...
When is a TIPS procedure indicated for a pediatric patient with sinusoidal obstructive syndrome?
TIPS (transjugular intrahepatic portosystemic shunt) procedure is not indicated in children with sinusoidal obstructive syndrome and most literature on this topic (in adults) dates prior to 2000. In the largest adult series using TIPS for VOD in adults (D'Azoulay et al., PMID 10800068), out of 10 pa...
How do you approach the use of low-dose aspirin for primary prevention in non-pregnant patients with SLE and positive aPL antibodies, without clinical criteria for APS?
I personally do not put all asymptomatic SLE patients with aPL labs on low dose aspirin. This is a somewhat controversial topic. Most of the data we have are from observational studies and results are mixed in regards to efficacy of low dose aspirin for primary prevention in this population. SLE pat...
Would you use autologous hematopoietic stem cells collected from a HR neuroblastoma patient found to be COVID positive after harvest?
While the safest approach might be to try to do another collection once the patient has recovered, that may not be feasible or lead to delays in the transplant. I would use this product since transmission of SARS-CoV-2 is not systematic and there is no evidence of SARS-CoV-2 transfusion transmission...